News Agency
Men's Weekly

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

  • Written by PR Newswire

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai Yingli...

Read more: 280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in...

Why Choosing The Right Packaging Supplies Impacts Your Business Growth

In today’s competitive market, packaging is more than just a protective layer; it is a critical part of how businesses operate and present themselves. This is where packaging supplies Melbourne become essential, providing businesses with the tools needed to protect... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion